Novo Nordisk shares riding high on success of Wegovy

<img width="250" height="167" src="https://www.leaprate.com/wp-content/uploads/2023/10/FNP-LP-Success-of-Ozempic-kidney-failure-trials-proves-disastrous-for-dialysis-stocks-5318697040iStock-1219304819-250×167.jpg" class="webfeedsFeaturedVisual wp-post-image" alt="" decoding="async" style="float: left; margin-right: 5px;" link_thumbnail="" srcset="https://www.leaprate.com/wp-content/uploads/2023/10/FNP-LP-Success-of-Ozempic-kidney-failure-trials-proves-disastrous-for-dialysis-stocks-5318697040iStock-1219304819-250×167.jpg 250w, https://www.leaprate.com/wp-content/uploads/2023/10/FNP-LP-Success-of-Ozempic-kidney-failure-trials-proves-disastrous-for-dialysis-stocks-5318697040iStock-1219304819-700×466.jpg 700w, https://www.leaprate.com/wp-content/uploads/2023/10/FNP-LP-Success-of-Ozempic-kidney-failure-trials-proves-disastrous-for-dialysis-stocks-5318697040iStock-1219304819-768×512.jpg 768w, https://www.leaprate.com/wp-content/uploads/2023/10/FNP-LP-Success-of-Ozempic-kidney-failure-trials-proves-disastrous-for-dialysis-stocks-5318697040iStock-1219304819-120×80.jpg 120w, https://www.leaprate.com/wp-content/uploads/2023/10/FNP-LP-Success-of-Ozempic-kidney-failure-trials-proves-disastrous-for-dialysis-stocks-5318697040iStock-1219304819-245×163.jpg 245w, https://www.leaprate.com/wp-content/uploads/2023/10/FNP-LP-Success-of-Ozempic-kidney-failure-trials-proves-disastrous-for-dialysis-stocks-5318697040iStock-1219304819-500×333.jpg 500w, https://www.leaprate.com/wp-content/uploads/2023/10/FNP-LP-Success-of-Ozempic-kidney-failure-trials-proves-disastrous-for-dialysis-stocks-5318697040iStock-1219304819.jpg 1255w" sizes="(max-width: 250px) 100vw, 250px" /><p>This bullish stock performance follows on the heels of a key study that found Wegovy, the Novo Nordisk weight loss drug, reduces cardiac risks and related mortalities in obese people. Those involved in the study took the highest dose of the drug and consequently experienced a drop in blood sugar and inflammation, two of the portents of cardiac diseases.</p>
<p>Novo Nordisk shares gained roughly 52% this year, bringing its market valuation to more than $490bn. In October, the company stopped its <a href="https://www.leaprate.com/news/success-of-ozempic-kidney-failure-trials-proves-disastrous-for-dialysis-stocks/" target="_blank" rel="noopener">Ozempic</a> kidney trials early on the back of conclusive evidence that it aids kidney failure patients.</p>
<p>The company presented the positive Wegovy findings on Saturday in the United States. This follows the release of preliminary data in August from a larger study, which caused a 17% surge in Novo Nordisk shares.</p>
<hr />
<p><a href="https://finaffiliates.us20.list-manage.com/subscribe/post?u=e0dd4d77c259eb270712a4eeb&amp;id=fd200b8f75&amp;v_id=4291&amp;f_id=00946ce6f0" target="_blank" rel="noopener"><em>Don’t miss out the latest news, subscribe to LeapRate’s newsletter</em></a></p>
<hr />
<p>The August results indicated patients on Wegovy lose approximately 15% of weight and reduced heart attacks, strokes, and deaths directly related to cardiac conditions by 20%. As with Ozempic, semaglutide is the active ingredient in Wegovy.</p>
<p>Reuters reported that Markus Manns, a portfolio manager at Union Investment Germany, said these early cardiovascular benefits could be a significant determiner in the bid against competitors such as Amgen (AMGN.O) and Pfizer (PFE.N).</p>
<p>The post <a rel="nofollow" href="https://www.leaprate.com/news/novo-nordisk-shares-riding-high-on-success-of-wegovy/">Novo Nordisk shares riding high on success of Wegovy</a> appeared first on <a rel="nofollow" href="https://www.leaprate.com">LeapRate</a>.</p>